ReAlta Life Sciences, Inc.: Germany's BfArM Approves ReAlta Life Science's Phase 1b Inhaled LPS Challenge Trial to Support Development of RLS-0071 in Severe Asthma

RLS-0071 is ReAlta's lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases ReAlta

Related Keywords

Germany ,Norfolk ,Virginia ,United States ,Hannover ,Niedersachsen ,Dburns Mcclellan ,Ulrich Thienel ,Robert Flamm ,Kostenloser Wertpapierhandel ,Eric Ando ,Germany Federal Institute For Drugs ,Realta Life Sciences Inc ,European Medicines Agency ,Drug Administration ,Fraunhofer Institute For Toxicology ,Realta Life Sciences ,Malta Life Sciences ,Federal Institute ,Medical Devices ,Chief Executive ,Fraunhofer Institute ,Experimental Medicine ,Orphan Drug Designation ,Realta ,Life ,Ciences ,Farm ,Pproves ,Science ,Hase ,Inhaled ,Challenge ,Trial ,Support ,Development ,1071 ,Evere ,Asthma ,